Retroperitoneal sarcoma is rare. Using initial specimens on biopsy, a definitive diagnosis of histological subtypes is ideal but not always achievable.
Methods
A retrospective institutional review was performed for all cases of adult retroperitoneal sarcoma from 1996 to 2015. A review of the literature was also performed related to the distribution of retroperitoneal sarcoma subtypes. A meta-analysis was performed.
Results
Liposarcoma is the most common subtype (45%), followed by leiomyosarcoma (21%), not otherwise specified (8%), and undifferentiated pleomorphic sarcoma (6%) by literature review. Data from Moffitt Cancer Center demonstrate the same general distribution for subtypes of retroperitoneal sarcoma. A pathology-based algorithm for the diagnosis of retroperitoneal sarcoma is illustrated, and common pitfalls in the pathology of retroperitoneal sarcoma are discussed.
Conclusions
An informative diagnosis of retroperitoneal sarcoma via specimens on biopsy is achievable and meaningful to guide effective therapy. A practical and multidisciplinary algorithm focused on the histopathology is helpful for the management of retroperitoneal sarcoma.
References
1.
MullinaxJ.E., ZagerJ.S., GonzalezR.J.Current diagnosis and management of retroperitoneal sarcoma.Cancer Control.2011; 18(3): 177–187.
2.
MastrangeloG., CoindreJ.M., DucimetiereF.Incidence of softtissue sarcoma and beyond: a population-based prospective study in 3 European regions.Cancer.2012; 118(21): 5339–5348.
3.
DucimetiereF., LurkinA., Ranchere-VinceD.Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing.PLoS One.2011; 6(8): e20294.
4.
LilesJ.S., TzengC.W., ShortJ.J.Retroperitoneal and intra-abdominal sarcoma.Curr Probl Surg.2009; 46(6): 445–503.
5.
DoddL.G., BuiM.M.Atlas of Soft Tissue and Bone Pathology: With Histologic, Cytologic, and Radiologic Correlations.New York: Demos Medical; 2015.
6.
MatthyssensL.E., CreytensD., CeelenW.P.Retroperitoneal liposarcoma: current insights in diagnosis and treatment.Front Surg.2015; 2: 4.
7.
Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group.Ann Surg Oncol.2015; 22(1): 256–263.
8.
ItalianoA., DelvaF., Mathoulin-PelissierS.Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft-tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database.Ann Oncol.2010; 21(12): 2436–2441.
9.
JonesR.L., FisherC., Al-MuderisO.Differential sensitivity of liposarcoma subtypes to chemotherapy.Eur J Cancer.2005; 41(18): 2853–2860.
10.
SleijferS., OualiM., van GlabbekeM.Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft-tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).Eur J Cancer.2010; 46(1): 72–83.
11.
SeddonB., ScurrM., JonesR.L.A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.Clin Sarcoma Res.2015; 5: 13.
12.
Van GlabbekeM., van OosteromA.T., OosterhuisJ.W.Prognostic factors for the outcome of chemotherapy in advanced soft-tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens–a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.J Clin Oncol.1999; 17(1): 150–157.
13.
KroepJ.R., OualiM., GelderblomH.First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft-tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study.Ann Oncol.2011; 22(1): 207–214.
14.
ThomasD.M., O'SullivanB., GronchiA.Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management.Expert Rev Anticancer Ther.2009; 9(8): 1145–1157.
15.
SaynakM., Bayir-AnginG., KocakZ.Recurrent solitary fibrous tumor of the pleura: significant response to radiotherapy.Med Oncol.2010; 27(1): 45–48.
KneislJ.S., ColemanM.M., RautC.P.Outcomes in the management of adult soft-tissue sarcomas.J Surg Oncol.2014; 110(5): 527–538.
18.
TuanJ., VitoloV., VischioniB.Radiation therapy for retroperitoneal sarcoma.Radiol Med.2014; 119(10): 790–802.
19.
StoeckleE., CoindreJ.M., BonvalotS.Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group.Cancer.2001; 92(2): 359–368.
20.
MericF., HessK.R., VarmaD.G.Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in softtissue sarcomas.Cancer.2002; 95(5): 1120–1126.
21.
WendtnerC.M., Abdel-RahmanS., KrychM.Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft-tissue sarcomas.J Clin Oncol.2002; 20(14): 3156–3164.
22.
MericF., MilasM., HuntK.K.Impact of neoadjuvant chemotherapy on postoperative morbidity in soft-tissue sarcomas.J Clin Oncol.2000; 18(19): 3378–3383.
23.
DonahueT.R., KattanM.W., NelsonS.D.Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram.Cancer.2010; 116(16): 3883–3891.
24.
JudsonI., VerweijJ., GelderblomH.Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.Lancet Oncol.2014; 15(4): 415–423.
25.
KrikelisD., JudsonI.Role of chemotherapy in the management of soft-tissue sarcomas.Expert Rev Anticancer Ther.2010; 10(2): 249–260.
26.
YoungR.J., NatukundaA., LitiereS.First-line anthracycline-based chemotherapy for angiosarcoma and other soft-tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.Eur J Cancer.2014; 50(18): 3178–3186.
27.
ConstantinidouA., JonesR.L., OlmosD.Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour.Acta Oncol.2012; 51(4): 550–554.
28.
ConstantinidouA., PollackS., LoggersE.The evolution of systemic therapy in sarcoma.Expert Rev Anticancer Ther.2013; 13(2): 211–223.
29.
HoekstraH.J., ThijssensK., van GinkelR.J.Role of surgery as primary treatment and as intervention in the multidisciplinary treatment of soft tissue sarcoma.Ann Oncol.2004; 15(suppl 4): iv181–iv186.
30.
KaravasilisV., SeddonB.M., AshleyS.Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.Cancer.2008; 112(7): 1585–1591.
31.
NeuvilleA., ChibonF., CoindreJ.M.Grading of soft-tissue sarcomas: from histological to molecular assessment.Pathology.2014; 46(2): 113–120.
32.
HoffmanA., LazarA.J., PollockR.E.New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort.Drug Resist Updat.2011; 14(1): 52–66.
PayneW.G., NaiduD.K., WheelerC.K.Wound healing in patients with cancer.Eplasty.2008; 8: e9.
35.
ThomasT.O., HasanS., SmallW.The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far?J Gastrointest Oncol.2014; 5(3): 236–246.
CormierJ.N., PollockR.E.Soft tissue sarcomas.CA Cancer J Clin.2004; 54(2): 94–109.
38.
PerezE.A., GutierrezJ.C., MoffatF.L.Jr. Retroperitoneal and truncal sarcomas: prognosis depends upon type not location.Ann Surg Oncol.2007; 14(3): 1114–1122.
39.
GronchiA., MiceliR., ShurellE.Outcome prediction in primary resected retroperitoneal soft-tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets.J Clin Oncol.2013; 31(13): 1649–1655.
40.
StojadinovicA., YehA., BrennanM.F.Completely resected recurrent soft-tissue sarcoma: primary anatomic site governs outcomes.J Am Coll Surg.2002; 194(4): 436–447.
41.
AnayaD.A., LevD.C., PollockR.E.The role of surgical margin status in retroperitoneal sarcoma.J Surg Oncol.2008; 98(8): 607–610.
42.
ToulmondeM., BonvalotS., MeeusP.Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.Ann Oncol.2014; 25(3): 735–742.
43.
de VreezeR.S., de JongD., TielenI.H.Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis.Mod Pathol.2009; 22(2): 223–231.
44.
ZaydfudimV., OkunoS.H., QueF.G.Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors.J Surg Res.2012; 177(2): 248–254.
45.
FioreM., PalassiniE., FumagalliE.Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).Eur J Surg Oncol.2009; 35(7): 739–745.
46.
FletcherC.D.; World Health Organization; International Agency for Research on Cancer.WHO Classification of Tumours of Soft Tissue and Bone.4th ed.Lyon: IARC Press; 2013.
47.
Dal CinP., KoolsP., SciotR.Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors.Cancer Genet Cytogenet.1993; 68(2): 85–90.
48.
KarakousisC.P., Dal CinP., Turc-CarelC.Chromosomal changes in soft-tissue sarcomas. A new diagnostic parameter.Arch Surg.1987; 122(11): 1257–1260.
49.
PedeutourF., SuijkerbuijkR.F., ForusA.Complex composition and co-amplification of SAS and MDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcoma.Genes Chromosomes Cancer.1994; 10(2): 85–94.
50.
IkomaN., TorresK.E., SomaiahN.Accuracy of preoperative percutaneous biopsy for the diagnosis of retroperitoneal liposarcoma subtypes.Ann Surg Oncol.2015; 22(4): 1068–1072.
51.
WeaverJ., RaoP., GoldblumJ.R.Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma?Mod Pathol.2010; 23(10): 1301–1306.
52.
ChibonF., MarianiO., DerreJ.A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas.Cancer Genet Cytogenet.2002; 139(1): 24–29.
53.
CoindreJ.M., HosteinI., MaireG.Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity.J Pathol.2004; 203(3): 822–830.
54.
CoindreJ.M., MarianiO., ChibonF.Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma.Mod Pathol.2003; 16(3): 256–262.
55.
Dei TosA.P., DoglioniC., PiccininS.Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours.J Pathol.2000; 190(5): 531–536.
56.
GisselssonD., HoglundM., MertensF.Chromosomal organization of amplified chromosome 12 sequences in mesenchymal tumors detected by fluorescence in situ hybridization.Genes Chromosomes Cancer.1998; 23(3): 203–212.
57.
PedeutourF., ForusA., CoindreJ.M.Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors.Genes Chromosomes Cancer.1999; 24(1): 30–41.
58.
CoindreJ.M., PedeutourF., AuriasA.Well-differentiated and dedifferentiated liposarcomas.Virchows Arch.2010; 456(2): 167–179.
59.
McCormickD., MentzelT., BehamA.Dedifferentiated liposarcoma. Clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas.Am J Surg Pathol.1994; 18(12): 1213–1223.
60.
WeissS.W., RaoV.K.Well-differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous sites. A follow-up study of 92 cases with analysis of the incidence of “dedifferentiation.”Am J Surg Pathol.1992; 16(11): 1051–1058.
61.
ElgarF., GoldblumJ.R.Well-differentiated liposarcoma of the retroperitoneum: a clinicopathologic analysis of 20 cases, with particular attention to the extent of low-grade dedifferentiation.Mod Pathol.1997; 10(2): 113–120.
62.
HenricksW.H., ChuY.C., GoldblumJ.R.Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation.Am J Surg Pathol.1997; 21(3): 271–281.
63.
SioleticS., Dal CinP., FletcherC.D.Well-differentiated and dedifferentiated liposarcomas with prominent myxoid stroma: analysis of 56 cases.Histopathology.2013; 62(2): 287–293.
64.
KransdorfM.J., MurpheyM.D.Imaging of Soft Tissue Tumors.2nd ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
65.
WeissS.W.Smooth muscle tumors of soft tissue.Adv Anat Pathol.2002; 9(6): 351–359.
MentzelT., CalonjeE., FletcherC.D.Leiomyosarcoma with prominent osteoclast-like giant cells. Analysis of eight cases closely mimicking the so-called giant cell variant of malignant fibrous histiocytoma.Am J Surg Pathol.1994; 18(3): 258–265.
68.
MerchantW., CalonjeE., FletcherC.D.Inflammatory leiomyosarcoma: a morphological subgroup within the heterogeneous family of so-called inflammatory malignant fibrous histiocytoma.Histopathology.1995; 27(6): 525–532.
69.
KingM.E., DickersinG.R., ScullyR.E.Myxoid leiomyosarcoma of the uterus. A report of six cases.Am J Surg Pathol.1982; 6(7): 589–598.
NistalM., PaniaguaR., PicazoM.L.Granular changes in vascular leiomyosarcoma.Virchows Arch A Pathol Anat Histol.1980; 386(2): 239–248.
72.
OdaY., MiyajimaK., KawaguchiK.Pleomorphic leiomyosarcoma: clinicopathologic and immunohistochemical study with special emphasis on its distinction from ordinary leiomyosarcoma and malignant fibrous histiocytoma.Am J Surg Pathol.2001; 25(8): 1030–1038.
73.
RangdaengS., TruongL.D.Comparative immunohistochemical staining for desmin and muscle-specific actin. A study of 576 cases.Am J Clin Pathol.1991; 96(1): 32–45.
74.
SwansonP.E., StanleyM.W., ScheithauerB.W.Primary cutaneous leiomyosarcoma. A histological and immunohistochemical study of 9 cases, with ultrastructural correlation.J Cutan Pathol.1988; 15(3): 129–141.
75.
HisaokaM., Wei-QiS., JianW.Specific but variable expression of h-caldesmon in leiomyosarcomas: an immunohistochemical reassessment of a novel myogenic marker.Appl Immunohistochem Mol Morphol.2001; 9(4): 302–308.
76.
WatanabeK., KusakabeT., HoshiN.h-Caldesmon in leiomyosarcoma and tumors with smooth muscle cell-like differentiation: its specific expression in the smooth muscle cell tumor.Hum Pathol.1999; 30(4): 392–396.
77.
WatanabeK., TajinoT., SekiguchiM.h-Caldesmon as a specific marker for smooth muscle tumors. Comparison with other smooth muscle markers in bone tumors.Am J Clin Pathol.2000; 113(5): 663–668.
78.
BrownD.C., TheakerJ.M., BanksP.M.Cytokeratin expression in smooth muscle and smooth muscle tumours.Histopathology.1987; 11(5): 477–486.
79.
MiettinenM.Immunoreactivity for cytokeratin and epithelial membrane antigen in leiomyosarcoma.Arch Pathol Lab Med.1988; 112(6): 637–640.
80.
MiettinenM.Keratin subsets in spindle cell sarcomas. Keratins are widespread but synovial sarcoma contains a distinctive keratin polypeptide pattern and desmoplakins.Am J Pathol.1991; 138(2): 505–513.
81.
IwataJ., FletcherC.D.Immunohistochemical detection of cytokeratin and epithelial membrane antigen in leiomyosarcoma: a systematic study of 100 cases.Pathol Int.2000; 50(1): 7–14.
82.
KelleyT.W., BordenE.C., GoldblumJ.R.Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study.Appl Immunohistochem Mol Morphol.2004; 12(4): 338–341.
83.
KhalidiH.S., SingletonT.P., WeissS.W.Inflammatory malignant fibrous histiocytoma: distinction from Hodgkin's disease and non-Hodgkin's lymphoma by a panel of leukocyte markers.Mod Pathol.1997; 10(5): 438–442.
84.
GazziolaC., CordaniN., WassermanB.Malignant fibrous histiocytoma: a proposed cellular origin and identification of its characterizing gene transcripts.Int J Oncol.2003; 23(2): 343–351.
85.
Al-AghaO.M., IgbokweA.A.Malignant fibrous histiocytoma: between the past and the present.Arch Pathol Lab Med.2008; 132(6): 1030–1035.
86.
LarramendyM.L., GentileM., SoloneskiS.Does comparative genomic hybridization reveal distinct differences in DNA copy number sequence patterns between leiomyosarcoma and malignant fibrous histiocytoma?Cancer Genet Cytogenet.2008; 187(1): 1–11.
87.
CarneiroA., FrancisP., BendahlP.O.Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin?Lab Invest.2009; 89(6): 668–675.
JainM., ShubhaB.S., SethiS.Retroperitoneal ganglioneuroma: report of a case diagnosed by fine-needle aspiration cytology, with review of the literature.Diagn Cytopathol.1999; 21(3): 194–196.
90.
DragoG., PasquierB., PasquierD.Malignant peripheral nerve sheath tumor arising in a “de novo” ganglioneuroma: a case report and review of the literature.Med Pediatr Oncol.1997; 28(3): 216–222.
91.
de ChadarevianJ.P., MaePascasioJ., HalliganG.E.Malignant peripheral nerve sheath tumor arising from an adrenal ganglioneuroma in a 6-year-old boy.Pediatr Dev Pathol.2004; 7(3): 277–284.
92.
FletcherC.D., DaviesS.E., McKeeP.H.Cellular schwannoma: a distinct pseudosarcomatous entity.Histopathology.1987; 11(1): 21–35.
93.
WoodruffJ.M., GodwinT.A., ErlandsonR.A.Cellular schwannoma: a variety of schwannoma sometimes mistaken for a malignant tumor.Am J Surg Pathol.1981; 5(8): 733–744.
94.
CasadeiG.P., ScheithauerB.W., HiroseT.Cellular schwannoma. A clinicopathologic, DNA flow cytometric, and proliferation marker study of 70 patients.Cancer.1995; 75(5): 1109–1119.
95.
LoddingP., KindblomL.G., AngervallL.Cellular schwannoma. A clinicopathologic study of 29 cases.Virchows Arch A Pathol Anat Histopathol.1990; 416(3): 237–248.
96.
WhiteW., ShiuM.H., RosenblumM.K.Cellular schwannoma. A clinicopathologic study of 57 patients and 58 tumors.Cancer.1990; 66(6): 1266–1275.
97.
WeissS.W., LanglossJ.M., EnzingerF.M.Value of S-100 protein in the diagnosis of soft tissue tumors with particular reference to benign and malignant Schwann cell tumors.Lab Invest.1983; 49(3): 299–308.
98.
KaramchandaniJ.R., NielsenT.O., van de RijnM.Sox10 and S100 in the diagnosis of soft-tissue neoplasms.Appl Immunohistochem Mol Morphol.2012; 20(5): 445–450.
99.
NiwaT., AidaN., FujitaK.Diffusion-weighted imaging of retroperitoneal malignant peripheral nerve sheath tumor in a patient with neurofibromatosis type 1.Magn Reson Med Sci.2008; 7(1): 49–53.
100.
YanB., MengX., ShiB.A retroperitoneal NF1-independent malignant peripheral nerve sheath tumor with elevated serum CA125: case report and discussion.J Neurooncol.2012; 109(1): 205–211.
101.
deCouJ.M., RaoB.N., ParhamD.M.Malignant peripheral nerve sheath tumors: the St. Jude Children's Research Hospital experience.Ann Surg Oncol.1995; 2(6): 524–529.
102.
DaimaruY., HashimotoH., EnjojiM.Malignant “triton” tumors: a clinicopathologic and immunohistochemical study of nine cases.Hum Pathol.1984; 15(8): 768–778.
103.
ZouC., SmithK.D., LiuJ.Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.Ann Surg.2009; 249(6): 1014–1022.
104.
MatsunouH., ShimodaT., KakimotoS.Histopathologic and immunohistochemical study of malignant tumors of peripheral nerve sheath (malignant schwannoma).Cancer.1985; 56(9): 2269–2279.
105.
NakajimaT., WatanabeS., SatoY.An immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissues.Am J Surg Pathol.1982; 6(8): 715–727.
106.
WickM.R., SwansonP.E., ScheithauerB.W.Malignant peripheral nerve sheath tumor. An immunohistochemical study of 62 cases.Am J Clin Pathol.1987; 87(4): 425–433.
107.
TerryJ., SaitoT., SubramanianS.TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies.Am J Surg Pathol.2007; 31(2): 240–246.
108.
KosemehmetogluK., VranaJ.A., FolpeA.L.TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms.Mod Pathol.2009; 22(7): 872–878.
109.
NonakaD., ChiribogaL., RubinB.P.Sox10: a pan-schwannian and melanocytic marker.Am J Surg Pathol.2008; 32(9): 1291–1298.
PekmezciM., ReussD.E., HirbeA.C.Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas.Mod Pathol.2015; 28(2): 187–200.
114.
McMasterM.J., SouleE.H., IvinsJ.C.Hemangiopericytoma. A clinicopathologic study and long-term followup of 60 patients.Cancer.1975; 36(6): 2232–2244.
115.
NielsenG.P., O'ConnellJ.X., DickersinG.R.Solitary fibrous tumor of soft tissue: a report of 15 cases, including 5 malignant examples with light microscopic, immunohistochemical, and ultrastructural data.Mod Pathol.1997; 10(10): 1028–1037.
116.
GoldJ.S., AntonescuC.R., HajduC.Clinicopathologic correlates of solitary fibrous tumors.Cancer.2002; 94(4): 1057–1068.
117.
GenglerC., GuillouL.Solitary fibrous tumour and haemangiopericytoma: evolution of a concept.Histopathology.2006; 48(1): 63–74.
118.
Vallat-DecouvelaereA.V., DryS.M., FletcherC.D.Atypical and malignant solitary fibrous tumors in extrathoracic locations: evidence of their comparability to intra-thoracic tumors.Am J Surg Pathol.1998; 22(12): 1501–1511.
119.
SusterS., NascimentoA.G., MiettinenM.Solitary fibrous tumors of soft tissue. A clinicopathologic and immunohistochemical study of 12 cases.Am J Surg Pathol.1995; 19(11): 1257–1266.
120.
van de RijnM., LombardC.M., RouseR.V.Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum, and lung.Am J Surg Pathol.1994; 18(8): 814–820.
121.
ChilosiM., FacchetttiF., Dei TosA.P.Bcl-2 expression in pleural and extrapleural solitary fibrous tumours.J Pathol.1997; 181(4): 362–367.
122.
HanauC.A., MiettinenM.Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites.Hum Pathol.1995; 26(4): 440–449.
123.
HasegawaT., HiroseT., SekiK.Solitary fibrous tumor of the soft tissue. An immunohistochemical and ultrastructural study.Am J Clin Pathol.1996; 106(3): 325–331.
124.
MohajeriA., TayebwaJ., CollinA.Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, non-random secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor.Genes Chromosomes Cancer.2013; 52(10): 873–886.
125.
YoshidaA., TsutaK., OhnoM.STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors.Am J Surg Pathol.2014; 38(4): 552–559.
KimY.W., ChoiS.J., JeonU.B.Retroperitoneal fibromatosis presenting as a presacral mass.Acta Radiol Short Rep.2014; 3(2): 2047981614523760.
132.
LiL., LangJ., FanQ.Primary pelvic retroperitoneal tumors: clinical analysis of 36 cases.Zhonghua Fu Chan Ke Za Zhi.2014; 49(11): 838–841.
133.
MohosE., KovacsT., BrittigF.Desmoid tumors in three patients.Magy Seb.2001; 54(6): 387–392.
134.
PopowiczW., DrzewieckiL., MurawaD.Desmoids: report of cases.Pol Merkur Lekarski.2003; 15(90): 554–555.
135.
ShihL.Y., WeiC.K., LinC.W.Postoperative retroperitoneal desmoid tumor mimics recurrent gastrointestinal stromal tumor: a case report.World J Gastroenterol.2012; 18(42): 6172–6176.
136.
UmemotoS., MakuuchiH., AmemiyaT.Intra-abdominal desmoid tumors in familial polyposis coli: a case report of tumor regression by prednisolone therapy.Dis Colon Rectum.1991; 34(1): 89–93.
137.
WhittleP.C., SanchezR.L., AlbarracinG.J.Retroperitoneal fibromatosis: report of a case.Rev Med Chil.2006; 134(1): 85–89.
138.
LazarA.J., TuvinD., HajibashiS.Specific mutations in the betacatenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.Am J Pathol.2008; 173(5): 1518–1527.
139.
WenigerM., D'HaeseJ.G., KunzW.En-bloc resection of a giant retroperitoneal lipoma: a case report and review of the literature.BMC Res Notes.2015; 8: 75.
140.
SaitoS.Retroperitoneal lipoma presenting with nutcracker-like phenomenon.Case Rep Urol.2013; 2013: 893242.
141.
WeiD., ShenL., YangK.Giant retroperitoneal lipoma in a pregnant patient.J Obstet Gynaecol.2013; 33(5): 522.
142.
ChanderB., KrishnaM., ThakurS.Extremely rare giant retroperitoneal fibrolipoma: a case report.J Cancer Res Ther.2012; 8(2): 314–316.
UkitaS., KoshiyamaM., OhnakaM.Retroperitoneal lipoma arising from the urinary bladder.Rare Tumors.2009; 1(1): e13.
145.
IdaC.M., WangX., Erickson-JohnsonM.R.Primary retroperitoneal lipoma: a soft tissue pathology heresy?: report of a case with classic histologic, cytogenetics, and molecular genetic features.Am J Surg Pathol.2008; 32(6): 951–954.
146.
DropA., Czekajska-ChehabE., MaciejewskiR.Giant retroperitoneal lipomas–radiological case report.Ann Univ Mariae Curie Sklodowska Med.2003; 58(2): 142–146.
147.
MartinezC.A., PalmaR.T., WaisbergJ.Giant retroperitoneal lipoma: a case report.Arq Gastroenterol.2003; 40(4): 251–255.
148.
RaftopoulosI., LeeT., ByrneM.P.Image of the month: retroperitoneal lipoma.Arch Surg.2002; 137(7): 865–866.
149.
FoaC., MaingueneC., DupreF.Rearrangement involving chromosomes 1 and 8 in a retroperitoneal lipoma.Cancer Genet Cytogenet.2002; 133(2): 156–159.
